Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gauri R Varadhachary

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|October 3, 2018
High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic CancerSarah A Bannon, Maria F Montiel, Jennifer B Goldstein, et al.
Annals of Surgical Oncology|September 10, 2015
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyChristina L Roland, Matthew H G Katz, Ching-Wei D Tzeng, et al.
Annals of Surgical Oncology|October 30, 2014
Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancerChristina L Roland, Anthony D Yang, Matthew H G Katz, et al.
Annals of Surgery|January 3, 2020
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Journal of the American College of Surgeons|May 13, 2008
Borderline resectable pancreatic cancer: the importance of this emerging stage of diseaseMatthew H G Katz, Peter W T Pisters, Douglas B Evans, et al.
JAMA Oncology|April 19, 2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical TrialRachna T Shroff, Milind M Javle, Lianchun Xiao, et al.
The American Journal of Surgical Pathology|February 4, 2012
Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinomaDeyali Chatterjee, Matthew H Katz, Asif Rashid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progressionChristopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
Cancer|October 27, 2011
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcomeDeyali Chatterjee, Matthew H Katz, Asif Rashid, et al.
JAMA Surgery|July 16, 2020
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Cancer Prevention Research (Philadelphia, Pa.)|October 3, 2018
High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic CancerSarah A Bannon, Maria F Montiel, Jennifer B Goldstein, et al.
Annals of Surgical Oncology|September 10, 2015
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyChristina L Roland, Matthew H G Katz, Ching-Wei D Tzeng, et al.
Annals of Surgical Oncology|October 30, 2014
Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancerChristina L Roland, Anthony D Yang, Matthew H G Katz, et al.
Annals of Surgery|January 3, 2020
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Journal of the American College of Surgeons|May 13, 2008
Borderline resectable pancreatic cancer: the importance of this emerging stage of diseaseMatthew H G Katz, Peter W T Pisters, Douglas B Evans, et al.
JAMA Oncology|April 19, 2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical TrialRachna T Shroff, Milind M Javle, Lianchun Xiao, et al.
The American Journal of Surgical Pathology|February 4, 2012
Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinomaDeyali Chatterjee, Matthew H Katz, Asif Rashid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progressionChristopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
Cancer|October 27, 2011
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcomeDeyali Chatterjee, Matthew H Katz, Asif Rashid, et al.
JAMA Surgery|July 16, 2020
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Pageof 12